Provide search filter criteria
| Authors | Title | Year | Citation |
|---|---|---|---|
| Design of phase III clinical trials. | 2010 | Oncology Clinical Trials: Successful Design, Conduct, and Analysis. 2010;():. | |
| Research methods for clinical trials in personalized medicine: A systematic review. | 2014 | Lost In Translation: Barriers to Incentives for Translational Research in Medical Sciences. 2014;():. | |
| Targeted cancer clinical trials. | 2012 | Designs for Clinical Trials. 2012;():157-177. | |
| Adaptive Q-learning. | 2013 | From Probability to Statistics and Back: High-Dimensional Models and Processes -- A Festschrift in Honor of Jon A. Wellner. 2013;9():150-162. | |
| Proportional rate models for recurrent time event data under dependent censoring: A comparative study. | 2011 | Recent Advances in Biostatistics. 2011;4():123-141. | |
| Estimation of dynamic treatment regimes for complex outcomes: Balancing benefits and risks. | 2016 | Adaptive Treatment Strategies in Practice: Planning Trials and Analyzing Data for Personalized Medicine. 2016;():249-262. | |
| Dynamic treatment regimes. | 2016 | Cancer Clinical Trials: Current and Controversial Issues in Design and Analysis. 2016;():. | |
| Value search estimators for optimal dynamic treatment regimes. | 2016 | Adaptive Treatment Strategies in Practice: Planning Trials and Analyzing Data for Personalized Medicine. 2016;():135-155. | |
| Endpoints for cancer clinical trials. | 2016 | Cancer Clinical Trials: Current and Controversial Issues in Design and Analysis. 2016;():. | |
| Bayesian meta-experimental design for evaluating cardiovascular risk. | 2014 | Quantitative Evaluation if Safety in Drug Development: Design, Analysis and Reporting. 2014;():13-38. | |
| SAS Macro BSMED: Bayesian survival meta-experimental design using historical data. | 2016 | Pharmaceutical Statistics Using SAS. 2016;():. | |
| Bayesian frailty models for multi-state survival data. | 2016 | Statistical Applications from Clinical Trials and Personalized Medicine to Finance and Business Analytics. 2016;():. | |
| Dynamic spatial pattern recognition in count data. | 2016 | New Developments in Statistical Modeling, Inference and Application. 2016;():185-202. | |
| 2017 | Methods in Comparative Effectiveness Research. 2017;():. | ||
| Meta-analysis of genome-wide association studies: No efficiency gain in using individual participant data. | 2010 | Genet Epidemiol. 2010;34(1):60-6. Pub Med | |
| Bivariate random effects meta-analysis of diagnostic studies using generalized linear mixed models. | 2010 | Med Decis Making. 2010;30(4):499-508. Pub Med | |
| permGPU: Using graphics processing units in RNA microarray association studies. | 2010 | BMC Bioinformatics. 2010;11():329. Pub Med | |
| Robust test method for time-course microarray experiments. | 2010 | BMC Bioinformatics. 2010;11():391. Pub Med | |
| Improved doubly robust estimation when data are monotonely coarsened, with application to longitudinal studies with dropout. | 2011 | Biometrics. 2011;67(2):536-45. Pub Med | |
| Clinical trials data collection: When less is more. | 2010 | J Clin Oncol. 2010;28(34):5019-21. Pub Med | |
| Analysis of untyped SNPs: Maximum likelihood and imputation methods. | 2010 | Genet Epidemiol. 2010;34(8):803-15. Pub Med | |
| Evaluating haplotype effects in case-control studies via penalized-likelihood approaches: Prospective or retrospective analysis? | 2010 | Genet Epidemiol. 2010;34(8):892-911. Pub Med | |
| Bivariate random effects models for meta-analysis of comparative studies with binary outcomes: methods for the absolute risk difference and relative risk. | 2012 | Stat Methods Med Res. 2012;21(6):621-33. Pub Med | |
| Incorporating higher-order representative features improves prediction in network-based cancer prognosis analysis. | 2011 | BMC Med Genomics. 2011;4():5. Pub Med | |
| Identification of predictive pathways for non-hodgkin lymphoma prognosis. | 2010 | Cancer Inform. 2010;9():281-92. Pub Med | |
| Semiparametric inference for a 2-stage outcome-auxiliary-dependent sampling design with continuous outcome. | 2011 | Biostatistics. 2011;12(3):521-34. Pub Med | |
| Multiple testing of treatment-effect-modifying biomarkers in a randomized clinical trial with a survival endpoint. | 2011 | Stat Med. 2011;30(13):1502-18. Pub Med | |
| Reinforcement learning strategies for clinical trials in nonsmall cell lung cancer. | 2011 | Biometrics. 2011;67(4):1422-33. Pub Med | |
| Additive mixed effect model for clustered failure time data. | 2011 | Biometrics. 2011;67(4):1340-51. Pub Med | |
| Sample size and power determination in joint modeling of longitudinal and survival data. | 2011 | Stat Med. 2011;30(18):2295-309. Pub Med | |
| Multiple testing for gene sets from microarray experiments. | 2011 | BMC Bioinformatics. 2011;12():209. Pub Med | |
| Semiparametric estimation of treatment effect with time-lagged response in the presence of informative censoring. | 2011 | Lifetime Data Anal. 2011;17(4):566-93. Pub Med | |
| Studying gene and gene-environment effects of uncommon and common variants on continuous traits: a marker-set approach using gene-trait similarity regression. | 2011 | Am J Hum Genet. 2011;89(2):277-88. Pub Med | |
| Performance of rapid influenza H1N1 diagnostic tests: a meta-analysis. | 2012 | Influenza Other Respir Viruses. 2012;6(2):80-6. Pub Med | |
| A general framework for detecting disease associations with rare variants in sequencing studies. | 2011 | Am J Hum Genet. 2011;89(3):354-67. Pub Med | |
| Genome-wide association study identifies five new schizophrenia loci. | 2011 | Nat Genet. 2011;43(10):969-76. Pub Med | |
| Bayesian meta-experimental design: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. | 2012 | Biometrics. 2012;68(2):578-86. Pub Med | |
| Marginal hazard regression for correlated failure time data with auxiliary covariates. | 2012 | Lifetime Data Anal. 2012;18(1):116-38. Pub Med | |
| Variable selection for optimal treatment decision. | 2013 | Stat Methods Med Res. 2013;22(5):493-504. Pub Med | |
| Bayesian analysis on meta-analysis of case-control studies accounting for within-study correlation. | 2015 | Stat Methods Med Res. 2015;24(6):836-55. Pub Med | |
| Phase II cancer clinical trials with heterogeneous patient populations. | 2012 | J Biopharm Stat. 2012;22(2):312-28. Pub Med | |
| On sample size calculation for comparing survival curves under general hypothesis testing. | 2012 | J Biopharm Stat. 2012;22(3):485-95. Pub Med | |
| Semiparametric transformation rate model for recurrent event data. | 2011 | Stat Biosci. 2011;3(2):187-207. Pub Med | |
| Data for cancer comparative effectiveness research: past, present, and future potential. | 2012 | Cancer. 2012;118(21):5186-97. Pub Med | |
| Gene selection using iterative feature elimination random forests for survival outcomes. | 2012 | IEEE/ACM Trans Comput Biol Bioinform. 2012;9(5):1422-31. Pub Med | |
| A robust method for estimating optimal treatment regimes. | 2012 | Biometrics. 2012;68(4):1010-8. Pub Med | |
| Power and sample size calculations for SNP association studies with censored time-to-event outcomes. | 2012 | Genet Epidemiol. 2012;36(6):538-48. Pub Med | |
| ROC curve estimation under test-result-dependent sampling. | 2013 | Biostatistics. 2013;14(1):160-72. Pub Med | |
| Variable selection for covariate-adjusted semiparametric inference in randomized clinical trials. | 2012 | Stat Med. 2012;31(29):3789-804. Pub Med | |
| Marginal additive hazards model for case-cohort studies with multiple disease outcomes: an application to the Atherosclerosis Risk in Communities (ARIC) study. | 2013 | Biostatistics. 2013;14(1):28-41. Pub Med |